Trial Profile
A Phase I/II Study of the Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of HLA-DP0401/0402 Restricted Anti-MAGE-A3 TCR-Gene Engineered Lymphocytes and Aldesleukin
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs MAGE A3 specific T cells (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine
- Indications Cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Mar 2021 Status changed from active, no longer recruiting to completed.
- 20 Jun 2020 Status changed from recruiting to active, no longer recruiting.
- 12 May 2017 Planned End Date changed from 28 Dec 2018 to 27 Dec 2024.